Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas

Author(s): Herbert B. Newton.

Journal Name: Current Signal Transduction Therapy

Volume 8 , Issue 1 , 2013

Submit Manuscript
Submit Proposal

Abstract:

Bevacizumab is a humanised monoclonal antibody targeted to the vascular endothelial growth factor (VEGF). VEGF is the ligand for VEGF receptors (VEGFR), which are important for the development and maintenance of the angiogenic phenotype in high-grade solid tumors, including malignant gliomas. An overview of VEGF, VEGFR, and the pharmacology of bevacizumab will be presented. Bevacizumab is active in pre-clinical testing against glioma tissue cultures and xenograft models. In the clinical setting, in combination with irinotecan and other chemotherapy agents, it has shown significant activity in patients with glioblastoma multiforme (GBM) and other brain tumors. Objective responses on neuro-imaging have been noted in 30-60% of reported cases. Prolongation of progression-free survival and overall survival have also been suggested in many reports. Treatment of bevacizumab is associated with potential side effects, including thromboembolic disorders, fatigue, intracranial hemorrhage, proteinuria, hypertension, and bowel perforation.

Keywords: Bevacizumab, chemotherapy, vascular endothelial growth factor, angiogenesis, brain tumor, glioblastoma multiforme, glioma

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 8
ISSUE: 1
Year: 2013
Page: [25 - 35]
Pages: 11
DOI: 10.2174/1574362411308010005

Article Metrics

PDF: 9